626 results on '"Gill, Harinder"'
Search Results
2. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
3. Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
4. Rashtriya swsthya bima yojna in India- Implementation and impact
5. A study of accessibility, availability and quality of health services in Punjab
6. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
7. Eosinophilic Disorders and Systemic Mastocytosis
8. Management of Relapsed or Refractory AML
9. In the Pipeline: Emerging Therapy for CML
10. Prognostic Indicators in MDS and CMML
11. Molecular Landscape and Personalized Prognostic Prediction of MPNs
12. Treatment Algorithm for Primary and Secondary Myelofibrosis
13. In the Pipeline: Emerging Therapy for MDS and MDS/MPN
14. Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?
15. Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics
16. In the Pipeline—Emerging Therapy for ALL
17. Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML
18. Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation
19. Frontline Management of Acute Promyelocytic Leukemia
20. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
21. Prognostic Models for Primary and Secondary Myelofibrosis
22. Clonal Hematopoiesis and Its Functional Implications in MDS/AML
23. Role of IDH1/IDH2 Inhibitors in AML
24. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
25. Undiagnosed Hypertension in Vancouver’s Punjabi Sikh Community: A Cross-Sectional Study
26. Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study
27. Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.
28. Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?
29. CD3+CD4+ lymphoid neoplasm: diagnostic clues for plasmablastic lymphoma instead of peripheral T-cell lymphoma
30. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
31. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
32. Prioritising the psychosocial needs of young oncology patients: a call for comprehensive care
33. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
34. Responsiveness of Output & Prices to Monetary & Fiscal Shocks in India
35. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study
36. Clinical delineation, sex differences, and genotype–phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2
37. Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy
38. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report
39. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
40. Bomedemstat as an investigative treatment for myeloproliferative neoplasms
41. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
42. Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype
43. RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit—successes and challenges
44. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
45. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
46. ORAL arsenic trioxide to combat acute promyelocytic leukaemia
47. Rethinking Palliative Care in Psychiatry
48. POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
49. MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
50. Congenital heart defects : a clinical and genetic analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.